|CBD||obesity,weight loss in rats via experiment||Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents||Jun 2019|
Ingestion Method: 10, 20, and 40 mg/kg, ip|
Action Pathway: CB1,CB2
Taken together, the present findings suggest that CBD may have therapeutic potential in reducing binge eating and the development of obesity.
|WIN55,AM6545||weight loss,obesity in mice via experiment||Cannabinoid CB1 Receptors Inhibit Gut-Brain Satiation Signaling in Diet-Induced Obesity||Mar 2019|
Action Pathway: CB1|
Collectively, these results provide evidence that hyperphagia associated with DIO is driven by a mechanism that includes CB1R-mediated inhibition of gut-brain satiation signaling.
|Rimonabant||weight loss in humans via placebo trial||Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.||Apr 2005|
Ingestion Method: 5, 25mg/day|
CB1 blockade with rimonabant 20 mg, combined with a hypocaloric diet over 1 year, promoted significant decrease of bodyweight and waist circumference, and improvement in cardiovascular risk factors.
|Rimonabant||weight loss in humans via placebo trial (n=1036)||Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.||Nov 2005|
|Positive Selective CB1-receptor blockade with rimonabant significantly reduces body weight and waist circumference and improves the profile of several metabolic risk factors in high-risk patients who are overweight or obese and have an atherogenic dyslipidemia.|
|Rimonabant||weight loss in humans via placebo trial (n=3045)||Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.||Mar 2006|
Ingestion Method: 20mg/day|
Neutral In this multicenter trial, treatment with 20 mg/d of rimonabant plus diet for 2 years promoted modest but sustained reductions in weight and waist circumference and favorable changes in cardiometabolic risk factors. However, the trial was limited by a high drop-out rate and longer-term effects of the drug require further study.
|Rimonabant||weight loss,diabetes in humans via placebo trial (n=1047)||Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.||Nov 2006|
Ingestion Method: 5, 25mg/day|
Positive These data indicate that 20 mg/day rimonabant, in combination with diet and exercise, can produce a clinically meaningful reduction in bodyweight and improve HbA1c and a number of cardiovascular and metabolic risk factors in overweight or obese patients with type 2 diabetes inadequately controlled by metformin or sulphonylureas.
|Rimonabant||weight loss in humans via placebo trial (n=839)||Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.||Apr 2008|
|Negative After 18 months of treatment, the study failed to show an effect for rimonabant on disease progression for the primary end point (PAV) but showed a favorable effect on the secondary end point (TAV).|
|CBD||weight loss, appetite supress||Cannabinol and cannabidiol exert opposing effects on rat feeding patterns.||Sept 2012|
|Furthermore, cannabidiol reduced food intake in line with some existing reports, supporting the need for further mechanistic and behavioral work examining possible anti-obesity effects of cannabidiol.|
|cannabis||obesity,weight loss in humans via study||Are cannabis users less likely to gain weight? Results from a national 3-year prospective study.||Mar 2019|
|This new prospective study builds from anecdotes, pre-clinical studies and cross-sectional evidence on inverse associations linking cannabis use and obesity and shows an inverse cannabis-BMI increase association. Confirmatory studies with rigorous cannabis and BMI assays will be needed.|